Back to top
more

Medpace (MEDP)

(Delayed Data from NSDQ)

$333.45 USD

333.45
331,765

-0.35 (-0.10%)

Updated Oct 1, 2024 04:00 PM ET

After-Market: $334.83 +1.38 (0.41%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 25% (190 out of 252)

Industry: Medical Services

Better trading starts here.

Zacks News

QIAGEN's (QGEN) New Launch Expands US Syndromic Testing Menu

QIAGEN's (QGEN) new QIAstat-Dx Gastrointestinal Panel 2 offers fast and accurate identification of up to 16 common gastrointestinal pathogens.

Nalak Das headshot

Top 5 Non-Tech Winners YTD With More Potential for Growth

Five Nasdaq listed non-tech stocks that have provided more than 40% returns year to date and have more potential for growth. These are: COIN, MEDP, WING, TXRH, TSCO.

Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now

Innovations and a robust diabetes market outlook raise investors' optimism for Tandem Diabetes (TNDM).

Zimmer Biomet (ZBH) Procedure Recovery Aids Amid Macro Woes

Zimmer Biomet (ZBH) continues to record strong procedure volume in 2024 in both the Knees and Hips businesses, banking on an improved market scenario.

Bruker (BRKR) Launches neofleX MALDI-TOF/TOF MSI System

Bruker's (BRKR) neofleX is a versatile, high-performance and easy-to-use multiomics MSI system for biopharma, translational and clinical researchers.

Medpace (MEDP) Outpaces Stock Market Gains: What You Should Know

Medpace (MEDP) reachead $389.41 at the closing of the latest trading day, reflecting a +0.79% change compared to its last close.

Omnicell (OMCL) Gains From New Offerings Amid Cost Woes

With the EnlivenHealth platform, Omnicell (OMCL) is gaining momentum with cross-selling and up-selling communication solutions to existing customers.

QIAGEN (QGEN) Advances Precision Medicine With New QIAseq Kit

QIAGEN (QGEN) launches the new QIAseq Multimodal DNA/RNA Lib Kit, facilitating multiomic studies and advancing precision medicine.

Teleflex's (TFX) Urolift Drives Market Share, Macro Woes Stay

The commercialization of Teleflex's (TFX) UroLift in Japan has been a significant step toward making this therapy more broadly available to men suffering from BPH.

BioLife (BLFS) Progresses in Cell & Gene Therapy With CryoCase

BioLife's (BLFS) latest product, CryoCase, is compatible with various downstream processing systems, including its own Signata CT-5.

Charles River (CRL) Launches Viral Vector Tech Transfer Program

Charles River's (CRL) new Fast Track and Modular frameworks facilitate product development continuity via accelerated process transfer to its viral vector Center of Excellence.

QIAGEN (QGEN) Develops Test for Research and CDx Application

QIAGEN's (QGEN) next-generation sequencing test aims to aid personalized medicine research in solid tumor types, including ovarian cancer, and improve decentralized testing capabilities.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

Investors are optimistic about Globus Medical (GMED) led by strong musculoskeletal prospects and raised guidance.

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Zimmer Biomet (ZBH) Unlocks Growth Plan for Future Success

Zimmer Biomet (ZBH) outlines a path for compelling and long-term topline growth, improved operational profitability, and increased free cash flow generation.

SenesTech (SNES) to Gain Market With Evolve's Launch on Amazon

SenesTech (SNES) looks to leverage the convenience and reach of e-commerce to expand its market share.

Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor

Tandem Diabetes' (TNDM) Mobi insulin pump is now compatible with Dexcom G7 CGM.

Reasons to Hold Charles River (CRL) in Your Portfolio Now

Investors remain optimistic about Charles River (CRL), owing to its acquisitions, thriving DSA segment and financial stability.

Here is Why Growth Investors Should Buy Medpace (MEDP) Now

Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Inspira Technologies' (IINN) ART100 Gets FDA 510(k) Grant

Inspira Technologies' (IINN) ART100 recent approval highlights the company's innovative advancements in medical technology.

Exact Sciences (EXAS) Witnesses Rising Expenses, Competition

Exact Sciences (EXAS) has numerous competitors, given the large market for colorectal cancer screening.

Medpace (MEDP) Rises Higher Than Market: Key Facts

The latest trading day saw Medpace (MEDP) settling at $390.81, representing a +0.07% change from its previous close.

Exact Sciences (EXAS) to Showcase Favorable Research Outcome

Exact Sciences' (EXAS) latest study research result shows commitment to innovation and strategies that expand access to effective cancer screening and diagnostic tools for patients.

Here's Why Investors Should Retain ICON (ICLR) Stock Now

Investors remain optimistic about ICON (ICLR) due to its impressive strategic pacts and stable solvency.

Stereotaxis (STXS) Gets CE Recertification for Approved Products

Stereotaxis' (STXS) receives updated EU Quality Management System Certificate, which demonstrates compliance with MDR.